Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577449 | 0.92 | CHRM3 (0.61) | CHRM3SMN1; SMN2MAPTLMNATP53 | |
| SCHEMBL5577312 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2MAPTLMNATP53DRD2 | |
| SCHEMBL5577748 | 0.91 | CHRM3 (0.57) | CHRM3SMN1; SMN2MAPTLMNADRD4 | |
| SCHEMBL5577569 | 0.90 | TSHR (0.60) | CHRM3SMN1; SMN2MAPTLMNADRD4 | |
| SCHEMBL5577532 | 0.88 | DRD2 (0.55) | SMN1; SMN2MAPTLMNATP53DRD2 | |
| SCHEMBL5577822 | 0.88 | DRD2 (0.55) | CHRM3SMN1; SMN2MAPTLMNATP53 | |
| SCHEMBL5577882 | 0.88 | SMN1; SMN2 (0.59) | CHRM3SMN1; SMN2MAPTLMNATP53 | |
| SCHEMBL5577561 | 0.88 | SMN1; SMN2 (0.58) | CHRM3SMN1; SMN2MAPTLMNATP53 | |
| SCHEMBL5577816 | 0.88 | ALDH1A1 (0.62) | CHRM3SMN1; SMN2MAPTLMNATP53 | |
| SCHEMBL5577867 | 0.88 | CHRM3 (0.59) | CHRM3SMN1; SMN2MAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CHRM3 2099/4885SMN1; SMN2 2012/4885MAPT 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.